Democratic Senators pushed pharma companies beyond insulin pricing during a 10 May Health, Education, Labor and Pensions Committee hearing that was technically focused on the diabetes drug, offering manufacturers a crucial lesson in concession making: sometimes they get you out of the crosshairs, and sometimes they get you more requests for concessions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?